Neither result is a diagnosis on its own. A positive says the immune system has recognised TB proteins at some point in the past, and the work of deciding what that means next belongs to a clinician.
A screening TB test looks for immune memory, not for the bacteria themselves. Tuberculosis is caused by Mycobacterium tuberculosis, which travels in air breathed out by someone with active disease in the lungs or airway. In most people who inhale it, the immune system walls the organism off, the person has no symptoms and cannot pass it to anyone else, a contained state described as latent tuberculosis infection 1.
Both standard screening tools work the same indirect way. They present proteins made by the TB organism, either under the skin or to a blood sample in a tube, and look for whether T cells recognise them. Recognition means the immune system has encountered those proteins before. It does not reveal where the bacteria are, how many there are, whether they are multiplying, or when the encounter happened.
Direct tests do exist. Sputum smear, culture and molecular tests on airway samples or tissue look for the organism itself, and those are ordered when active disease is suspected rather than as a screen for someone without symptoms.
Latent infection matters because containment is not permanent in everyone. A share of people with latent infection later develop active disease, and the risk rises when immune defences weaken 1. That is the practical logic behind screening, to find infection before it becomes illness, so that a clinician has time to decide what should follow.
The skin test injects a small amount of tuberculin, a purified protein mixture derived from the TB organism, into the top layer of skin on the inner forearm. The injection raises a pale bleb that disappears within minutes. If your T cells have met TB proteins before, they recruit other immune cells to the site over the next two days, and the area becomes firm and raised.
You return 48 to 72 hours later so a trained person can read it. Reading means measuring the width of the firm, raised area across the forearm, not the width of any redness. Redness alone does not count. The millimetre measurement is then compared against a cut-off, and the cut-off is not the same for everyone, it is set lower for people considered higher risk and higher for people considered lower risk. That is why the same measurement can be called positive for one person and negative for another, and why the reading belongs to a clinician who knows your history.
The practical trade-offs are straightforward. The test needs no laboratory and no blood draw, which is why it remains widely used, and it is covered in reviews of the tools currently available for diagnosing latent infection 2. Against that, it needs two visits inside a narrow window, the measurement depends on the person reading it, and prior vaccination with BCG can produce a reaction that looks positive without any TB infection behind it 2.
One more quirk matters for people tested repeatedly. In someone infected long ago, a first skin test can wake up a faded immune memory, so a second test weeks later reads larger. That is why a two-step baseline is used in some serial testing settings, so a boosted reaction is not mistaken later for new infection.
The TB blood test (IGRA) needs one blood draw and no return visit. Your blood is collected into tubes that contain proteins specific to the TB organism, along with control tubes. If T cells in the sample have met those proteins before, they respond by releasing signalling chemicals, and the laboratory measures how much appears. One widely used version is QuantiFERON-TB Gold Plus. Another platform counts the number of individual responding cells rather than measuring the chemical signal.
The laboratory reports a positive, negative or indeterminate result, and most platforms also report the raw values behind the call, which is why some results land close to the cut-off and get described as borderline.
Two design features matter to you as a reader. First, the proteins used are not present in the BCG vaccine strain and are absent from most environmental mycobacteria, so a BCG history does not usually push the blood test positive 2. Second, the test is a laboratory process with real handling requirements, tubes have to be filled correctly, mixed, and reach the laboratory inside a defined window at a controlled temperature, because the cells in the tube have to still be alive and responsive when the assay runs.
Research suggests that QuantiFERON-TB Gold Plus performs comparably to other available tests of latent tuberculosis infection 3. What it cannot do is separate a contained old infection from active disease, which is the single most common misunderstanding about the result.
There is no universal winner, the better test depends on your vaccination history, how likely you are to return for a reading, whether you are being tested repeatedly, and what the organisation requesting the test accepts. A clinician makes that call.
| Feature | Skin test | TB blood test (IGRA) |
|---|---|---|
| What it measures | A delayed skin reaction to tuberculin injected into the forearm | How T cells in a blood sample respond to TB-specific proteins |
| Visits needed | Two, one to place and one to read | One blood draw |
| Timing | Read 48 to 72 hours after placement | Processed in the laboratory after collection |
| Who interprets it | A trained person measures the firm raised area in millimetres | The laboratory reports the result from measured values |
| Prior BCG vaccination | Can produce a reaction unrelated to TB infection | Built around proteins absent from the vaccine strain |
| Possible results | Positive or negative against a risk-based cut-off | Positive, negative or indeterminate, sometimes borderline |
| Separates latent from active | No | No |
| Effect of repeat testing | A prior test can boost a later reaction | No boosting effect from a previous draw |
| Main practical weakness | Two visits, reader variability, vaccine cross-reaction | Sample handling and transport, indeterminate results |
Studies indicate that QuantiFERON tests detect latent tuberculosis infection with pooled performance supporting their use for screening, although estimates vary across the populations studied 4. In practice, the blood test is often favoured for people with a BCG history or for anyone unlikely to return for a skin reading, while the skin test remains useful where laboratory access or cost is the limiting factor. Some programmes specify one or the other, which settles the question before preference enters into it.
No, and this is the hard limit of both tools. Evidence suggests that these tests cannot by themselves distinguish contained latent infection from active tuberculosis disease, which is why a positive result triggers a clinical evaluation rather than a conclusion 5.
The reason sits in what is being measured. Both tests read immune memory, and immune memory looks similar whether the organism is dormant in a contained focus or actively multiplying in lung tissue. The T cell response persists for years after the original encounter, so the test cannot date the exposure either.
Separating the two states requires different information. A clinician asks about symptoms such as a cough lasting weeks, coughing blood, fever, night sweats and unexplained weight loss. Chest imaging looks for changes suggesting active disease. If anything points that way, sputum or other samples go for smear, culture and molecular testing, which look for the organism directly rather than for the body's memory of it. Only that sequence addresses the active question.
The order matters clinically, because the decision after a positive screen differs depending on which state a person is in, and treatment decisions belong to a licensed provider in either case. If you have symptoms that could fit active disease, that is worth discussing with a clinician promptly rather than waiting on a screening result to settle it.
A positive result means your immune system reacted to TB proteins, which is consistent with having been infected at some point. That is the observation. The inference stops there.
What it does not mean is worth being precise about. It does not mean you are ill. It does not mean you are contagious, because latent infection is not transmissible. It does not tell you when the exposure happened, whether it was last year or decades ago. And it does not always mean TB at all, because a skin test can react to BCG vaccination or to some environmental mycobacteria, and any test produces occasional false positives, especially when used in people at low risk of ever having been exposed 2.
The next step after a positive screen is clinical, not laboratory. A clinician reviews your exposure history and symptoms, arranges chest imaging, and considers further sampling if anything suggests active disease 5. Only after that does the question of preventive management arise, and that decision rests with a licensed provider who weighs your individual risk, your other conditions and anything else you are prescribed.
One practical point. A positive result is worth documenting and keeping, because repeating the same screening test later is generally uninformative once the immune memory has been recorded. Future screening in that situation usually means symptom review and imaging rather than another skin or blood test.
Less than most people assume. A negative result means no measurable immune response was detected on the day of testing, which is reassuring in a person at low risk and considerably less reassuring in several specific situations.
The first is timing. After a genuine exposure, the T cell response takes weeks to develop, so a test performed soon after contact can be negative while infection is still establishing. This is why contact investigations commonly repeat testing after the window has passed rather than acting on a single early negative.
The second is immune status. Both tests depend on T cells mounting a measurable response, so anything that blunts T cell function can blunt the test. That includes conditions that lower immune function and some medicines, and if you are prescribed something long term, ask your prescriber whether it affects screening interpretation. In people with significant immune suppression, a negative screening result carries less weight, and clinicians read it alongside exposure history rather than as a closed question 1.
The third is active disease itself. A person who is genuinely unwell with tuberculosis can still screen negative, which is another reason symptoms outrank a screening result. If symptoms that could fit active disease are present, a negative screen does not end the evaluation.
So a negative result is useful information with boundaries around it. Never treat it as permission to ignore a known exposure or a persistent symptom, and never discard an abnormal or unexpected result without discussing it.
An indeterminate result means the laboratory could not interpret your sample, usually because the built-in control tubes did not behave as expected. It is not a third category of answer about your TB status, it is a statement that the assay did not produce a readable one.
Two broad causes sit behind it. One is biological. The positive control tube checks that your T cells can respond at all, and if the response is weak, the assay cannot distinguish a true negative from a sample that simply could not react. Low or poorly responsive lymphocyte numbers, significant illness at the time of the draw and immune-suppressing conditions all push in that direction. The other cause is technical. Incorrect fill volume, inadequate mixing, delays reaching the laboratory and temperature excursions during transport all degrade the cells in the tube before the assay runs.
The practical response is usually to repeat the draw, sometimes with attention to handling, and sometimes to use the skin test instead so the question is asked a different way. Indeterminate and borderline results are among the recognised limitations of current tools for diagnosing latent infection, which is part of why work continues on additional biomarkers 6.
A borderline result is different from an indeterminate one. Borderline means the measured value sits close to the cut-off, so small day-to-day variation could tip it either way. That is a situation where repeat testing and clinical context matter more than the label on the report.
They disagree because they measure related but not identical things, in different tissues, against different thresholds. Studies suggest that agreement between the blood test and the skin test can be poor, including in people with rheumatoid arthritis and in healthy controls 7.
Several mechanisms contribute. The skin test uses a broad protein mixture that overlaps with BCG and with environmental mycobacteria, while the blood test uses a narrower set of TB-specific proteins, so a BCG-vaccinated person can plausibly be skin-test positive and blood-test negative. The skin test reads a whole-body response played out over two days in living tissue, while the blood test reads a response from cells isolated in a tube over a fixed incubation. Both use thresholds, and results near those thresholds flip easily. The skin test also carries reader variability, since measurement by hand is not perfectly reproducible between observers.
None of this makes either test wrong. It means neither is a perfect reference standard for latent infection, and reviews of current tools make that limitation explicit 2. When two tests disagree, a clinician weighs your exposure history, your BCG history, your immune status and the reason for testing, then decides whether the discordance changes anything. In many low-risk situations it does not. In a close contact of someone with active disease, it often does.
Screening is aimed at people with a reason to be screened, not at everyone. Guidance for lower-burden settings frames this as targeted testing of defined risk groups, because testing people at very low risk produces proportionally more false positives and more unnecessary follow-up than useful findings 8.
The groups usually considered include close contacts of someone diagnosed with active tuberculosis, people who have lived in or spent extended time in settings where tuberculosis is common, people who live or work in congregate settings, and people whose immune defences are reduced, whether by a medical condition or by something they are prescribed. If that last point applies to you, ask your prescriber whether screening is recommended before any change, since that conversation is routine rather than alarming.
Separately, many people are tested not because of personal risk but because an employer, a training programme or an immigration process requires it. In that case the organisation usually specifies which test it accepts, and the result is interpreted against the same clinical rules regardless of why it was ordered.
The value of targeting is practical. A positive result in someone with a real exposure history carries far more weight than the same result in someone with no plausible exposure, because the chance that a positive reflects true infection rises with the underlying likelihood of infection. That is one reason the decision to test at all belongs in a clinical conversation rather than on a checklist.
A positive screen starts a short, structured evaluation. The clinician asks about symptoms, reviews your exposure and vaccination history, and arranges chest imaging. If symptoms or imaging suggest active disease, sampling for direct testing follows. If nothing suggests active disease, the working interpretation is latent infection, and the conversation turns to whether preventive management is appropriate 5.
That decision is individual. It weighs how likely the infection is to progress in your particular situation, your other conditions, anything else you are prescribed, and your own preferences. Treatment decisions belong to a licensed provider who evaluates whether any option is appropriate for you. This page does not discuss options by name, and no article should be the place where that is settled.
One finding is worth knowing before you start the process. Research tracking people from screening through evaluation to completed preventive therapy has found losses at every step along the way, with a minority of those initially tested completing the full sequence 9. The practical lesson is simple. Book the follow-up appointment before you leave, keep a copy of your result, and tell any new clinician that you had a positive screen, because a documented positive is information that stays useful for the rest of your life.
Lymphocytes Absolute is the number of lymphocytes in a set volume of blood, and lymphocytes include the T cells the TB blood test depends on. FitScript's optimal range for this marker is 1.5 to 3 K/µL, against a typical lab reference range of 1 to 4 K/µL. Reference ranges vary by lab, age and sex, and the optimal range is an optimization target rather than a diagnostic cut-off. A low count does not invalidate a TB result by itself, and a normal count does not confirm one, but the two are sometimes read together when a blood test returns indeterminate. What this marker measures, how it is tested and what a high or low value may reflect are covered in full on its own guide.
A TB screen answers one narrow question, so the useful companions are the tests that describe the immune context around it. A complete blood count with differential shows the white cell lines, including lymphocytes, which is the population the blood test relies on. General inflammation markers such as CRP and ESR are non-specific, they rise with many things and point at nothing in particular, but they give a clinician a sense of whether something inflammatory is active. Imaging is the other obvious companion, since a chest X-ray answers a question no blood marker can.
Clinicians evaluating someone for tuberculosis infection also assess broader immune status, because conditions and treatments that reduce immune function change both the interpretation of a screening result and the urgency of acting on it 8. That assessment is part of the clinical visit rather than something to assemble yourself.
For context on the rest of your biology, FitScript tests 150+ biomarkers per year and Atlas, its AI health advisor, reads them together rather than one marker at a time. A TB screen sits outside that, it is ordered by a clinician or a public health service when exposure or risk justifies it, and the result is interpreted in a clinical setting.
Several things shift either the result itself or the interpretation placed on it, and most of them come out in the questions a clinician asks before testing.
None of these are reasons to distrust testing. They are the reasons a result is read by a clinician who knows the context rather than taken at face value from a printout.
Any positive, indeterminate or unexpected result is worth a conversation, and so is any symptom that could fit active disease regardless of what a test said. A cough persisting for weeks, coughing blood, fevers, drenching night sweats or unexplained weight loss are all worth discussing with a clinician promptly, because symptoms outrank screening results in deciding what happens next.
It is also worth raising if you have been in close contact with someone diagnosed with active tuberculosis, if you are about to start something that reduces immune function, or if an employer or programme has asked for screening and you are unsure which test applies to you. If you previously had a positive result, say so at any new clinical visit, because that single piece of history changes how a future cough is approached.
This page is educational and is not medical advice. Discuss your results and any treatment decision with a clinician or licensed provider who can see your full history, since no article can weigh your individual risk.
A skin test is placed at one visit and read in person 48 to 72 hours later, so you need to return inside that window or the test is repeated. The blood test needs one draw, and turnaround depends on the laboratory processing it, so ask the clinic that ordered it. Either way, the result is interpreted by a clinician alongside your history rather than read off the page alone.
No fasting or special preparation is required for either test. What does matter is telling the clinician about recent vaccinations, any condition affecting your immune system and anything you are prescribed, since ask your prescriber is the right route for medicine questions. Those details change how the result is read, not whether you can be tested.
Yes. A BCG history can produce a skin reaction that looks positive without TB infection behind it, which is why the blood test is often preferred in that situation, because it uses proteins that are not in the vaccine strain. The clinician ordering the test decides which option fits your circumstances and what the requesting organisation accepts.
No. A positive screening result means your immune system recognised TB proteins at some point, which is consistent with past infection, not with being ill or infectious. Latent infection is not transmissible. The clinician then reviews symptoms and arranges chest imaging to work out whether anything active is present, and any next step is their decision.
It means the laboratory could not interpret your sample, usually because the control tubes did not behave as expected. Weak cell responsiveness, illness on the day, and problems with tube filling, mixing or transport are the common reasons. The usual response is to repeat the draw or to use the skin test instead, and the clinician decides which.
Yes. The immune response takes weeks to develop after a genuine exposure, so a test done very early can read negative while infection is establishing. That is why contact investigations commonly repeat testing after that window has passed. Do not treat an early negative as a final answer if you had close contact with someone diagnosed with active tuberculosis.
Neither is a perfect reference standard, because both measure immune memory rather than the bacteria themselves, and they measure it in different ways. The blood test avoids BCG cross-reaction and needs only one visit. The skin test needs no laboratory. Which one suits you depends on your history, the reason for testing, and what the requesting organisation accepts.
Repeating the same screening test after a documented positive is generally uninformative, because the immune memory persists for years. Keep a copy of the result and mention it at any new clinical visit. Future assessment in that situation usually means symptom review and imaging rather than another skin or blood test, and the clinician sets the schedule.